Search Results - (Author, Cooperation:D. Coppola)
-
1Rho, J.-h., Ladd, J. J., Li, C. I., Potter, J. D., Zhang, Y., Shelley, D., Shibata, D., Coppola, D., Yamada, H., Toyoda, H., Tada, T., Kumada, T., Brenner, D. E., Hanash, S. M., Lampe, P. D.
BMJ Publishing Group
Published 2018Staff ViewPublication Date: 2018-02-09Publisher: BMJ Publishing GroupPrint ISSN: 0017-5749Electronic ISSN: 1468-3288Topics: MedicinePublished by: -
2Q. Fu ; C. Posth ; M. Hajdinjak ; M. Petr ; S. Mallick ; D. Fernandes ; A. Furtwangler ; W. Haak ; M. Meyer ; A. Mittnik ; B. Nickel ; A. Peltzer ; N. Rohland ; V. Slon ; S. Talamo ; I. Lazaridis ; M. Lipson ; I. Mathieson ; S. Schiffels ; P. Skoglund ; A. P. Derevianko ; N. Drozdov ; V. Slavinsky ; A. Tsybankov ; R. G. Cremonesi ; F. Mallegni ; B. Gely ; E. Vacca ; M. R. Morales ; L. G. Straus ; C. Neugebauer-Maresch ; M. Teschler-Nicola ; S. Constantin ; O. T. Moldovan ; S. Benazzi ; M. Peresani ; D. Coppola ; M. Lari ; S. Ricci ; A. Ronchitelli ; F. Valentin ; C. Thevenet ; K. Wehrberger ; D. Grigorescu ; H. Rougier ; I. Crevecoeur ; D. Flas ; P. Semal ; M. A. Mannino ; C. Cupillard ; H. Bocherens ; N. J. Conard ; K. Harvati ; V. Moiseyev ; D. G. Drucker ; J. Svoboda ; M. P. Richards ; D. Caramelli ; R. Pinhasi ; J. Kelso ; N. Patterson ; J. Krause ; S. Paabo ; D. Reich
Nature Publishing Group (NPG)
Published 2016Staff ViewPublication Date: 2016-05-03Publisher: Nature Publishing Group (NPG)Print ISSN: 0028-0836Electronic ISSN: 1476-4687Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsPublished by: -
3Staff View
ISSN: 1420-908XKeywords: Key words: 5-lipoxygenase inhibition — Five lipoxygenase activating protein (FLAP) — Dextran sulfate — Experimental colitis — Leukotriene B4— Inflammatory bowel diseaseSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract. Objective and Design: There is crucial evidence that leukotrienes are significant mediators of inflammation in inflammatory bowel diseases (IBD). Thus, selective inhibition of leukotriene synthesis is believed to provide a novel approach to therapy of IBD. The aim of the study is to study the efficacy of a potent 5-lipoxygenase activating protein inhibitor (FLAP), BAY y 1015 in a dextran sulfate model of mouse colitis.¶Material: Outbred female mice weighing approximately 25 grams were used to produce acute or chronic colitis by feeding 5% dextran sulfate in drinking water.¶Treatment: Colitic mice were treated with placebo (3% starch suspension, 0.1 ml. p.o., bid) or BAY y 1015 at 8 or 24 mg/kg, p.o., bid or olsalazine, 150 mg/kg/day, p.o.¶Methods: Efficacy was determined by measuring daily disease activity index (DAI), quantitative histological scores, qualitative histology and measurement of tissue myeloperoxidase (MPO) and leukotriene B4 (LTB4) levels.¶Results: BAY y 1015 was significantly more effective in improving the qualitative histology, inhibiting the DAI, inflammation scores (37–79%), crypt scores (28–71%), MPO (49–57%) and LTB4 levels (56–63%) compared to placebo treatment at all levels of colitis. The two doses of BAY y 1015 were equipotent in decreasing TLB4 levels. BAY y 1015 was significantly better than olsalazine in two of the three protocols used in this study. In the advanced disease level both doses of BAY y 1015 were equipotent in inhibiting crypt and (28–32%) inflammation scores (34–36%), LTB4 (34–56%) and MPO 41–49%) compared to olsalazine.¶Conclusion: This study suggests the possibility of investigating the use of this compound for the treatment of human inflammatory bowel diseases.Type of Medium: Electronic ResourceURL: -
4Staff View
ISSN: 1432-2218Source: Springer Online Journal Archives 1860-2000Topics: MedicineType of Medium: Electronic ResourceURL: